{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T13:39:11Z","timestamp":1793799551002,"version":"4.6.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T00:00:00Z","timestamp":1691625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T00:00:00Z","timestamp":1691625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["ID#68022735"],"award-info":[{"award-number":["ID#68022735"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-023-05418-y","type":"journal-article","created":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T23:24:01Z","timestamp":1691623441000},"page":"3009-3015","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Quantitative analysis of JAK\/STAT signaling pathway in patients of inflammatory skin disorders"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3186-0591","authenticated-orcid":false,"given":"Tuba","family":"Demirci Yildirim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5781-8506","authenticated-orcid":false,"given":"Asl\u0131","family":"Kahraman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4149-621X","authenticated-orcid":false,"given":"Aydan","family":"K\u00f6ken Av\u015far","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6341-2622","authenticated-orcid":false,"given":"Fatos","family":"Onen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3734-1242","authenticated-orcid":false,"given":"Servet","family":"Akar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7737-4180","authenticated-orcid":false,"given":"\u0130smail","family":"Sari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,10]]},"reference":[{"key":"5418_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/ANNRHEUMDIS-2012-202576","author":"JJ O\u2019Shea","year":"2013","unstructured":"O\u2019Shea JJ, Kontzias A, Yamaoka K et al (2013) Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/ANNRHEUMDIS-2012-202576","journal-title":"Ann Rheum Dis"},{"key":"5418_CR2","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/J.JAAD.2015.06.021","volume":"73","author":"SF Braswell","year":"2015","unstructured":"Braswell SF, Kostopoulos TC, Ortega-Loayza AG (2015) Pathophysiology of pyoderma gangrenosum (PG): an updated review. J Am Acad Dermatol 73:691\u2013698. https:\/\/doi.org\/10.1016\/J.JAAD.2015.06.021","journal-title":"J Am Acad Dermatol"},{"key":"5418_CR3","doi-asserted-by":"publisher","first-page":"3642","DOI":"10.1002\/ART.24959","volume":"60","author":"M Guma","year":"2009","unstructured":"Guma M, Ronacher L, Liu-Bryan R et al (2009) Caspase 1-independent activation of interleukin-1beta in neutrophil-predominant inflammation. Arthritis Rheum 60:3642\u20133650. https:\/\/doi.org\/10.1002\/ART.24959","journal-title":"Arthritis Rheum"},{"key":"5418_CR4","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/J.JAAD.2019.08.090","volume":"82","author":"SR Goldburg","year":"2020","unstructured":"Goldburg SR, Strober BE, Payette MJ (2020) Hidradenitis suppurativa: epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol 82:1045\u20131058. https:\/\/doi.org\/10.1016\/J.JAAD.2019.08.090","journal-title":"J Am Acad Dermatol"},{"key":"5418_CR5","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1111\/J.1365-2133.2011.10254.X","volume":"164","author":"HH Van Der Zee","year":"2011","unstructured":"Van Der Zee HH, De Ruiter L, Van Den Broecke DG et al (2011) Elevated levels of tumour necrosis factor (TNF)-\u03b1, interleukin (IL)-1\u03b2 and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-\u03b1 and IL-1\u03b2. Br J Dermatol 164:1292\u20131298. https:\/\/doi.org\/10.1111\/J.1365-2133.2011.10254.X","journal-title":"Br J Dermatol"},{"key":"5418_CR6","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1159\/000509873","volume":"237","author":"G Nikolakis","year":"2021","unstructured":"Nikolakis G, Kaleta KP, Vaiopoulos AG et al (2021) Phenotypes and pathophysiology of syndromic hidradenitis suppurativa: different faces of the same disease? A systematic review. Dermatology 237:673\u2013697. https:\/\/doi.org\/10.1159\/000509873","journal-title":"Dermatology"},{"key":"5418_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/NRDP.2016.39","author":"A Kaul","year":"2016","unstructured":"Kaul A, Gordon C, Crow MK et al (2016) Systemic lupus erythematosus. Nat Rev Dis Prim. https:\/\/doi.org\/10.1038\/NRDP.2016.39","journal-title":"Nat Rev Dis Prim"},{"key":"5418_CR8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/J.CBPA.2016.03.006","volume":"32","author":"K Yamaoka","year":"2016","unstructured":"Yamaoka K (2016) Janus kinase inhibitors for rheumatoid arthritis. Curr Opin Chem Biol 32:29\u201333. https:\/\/doi.org\/10.1016\/J.CBPA.2016.03.006","journal-title":"Curr Opin Chem Biol"},{"key":"5418_CR9","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.1021\/JM401490P","volume":"57","author":"JD Clark","year":"2014","unstructured":"Clark JD, Flanagan ME, Telliez JB (2014) Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. J Med Chem 57:5023\u20135038. https:\/\/doi.org\/10.1021\/JM401490P","journal-title":"J Med Chem"},{"key":"5418_CR10","doi-asserted-by":"publisher","first-page":"203","DOI":"10.5114\/REUM.2018.77971","volume":"56","author":"EJ Kucharz","year":"2018","unstructured":"Kucharz EJ, Stajszczyk M, Kotulska-Kucharz A et al (2018) Tofacitinib in the treatment of patients with rheumatoid arthritis: position statement of experts of the polish society for rheumatology. Reumatologia 56:203\u2013211. https:\/\/doi.org\/10.5114\/REUM.2018.77971","journal-title":"Reumatologia"},{"key":"5418_CR11","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1080\/1744666X.2018.1512404","volume":"14","author":"A Berekmeri","year":"2018","unstructured":"Berekmeri A, Mahmood F, Wittmann M, Helliwell P (2018) Tofacitinib for the treatment of psoriasis and psoriatic arthritis. Expert Rev Clin Immunol 14:719\u2013730. https:\/\/doi.org\/10.1080\/1744666X.2018.1512404","journal-title":"Expert Rev Clin Immunol"},{"key":"5418_CR12","doi-asserted-by":"publisher","DOI":"10.1177\/1756284819848631","author":"F D\u2019Amico","year":"2019","unstructured":"D\u2019Amico F, Parigi TL, Fiorino G et al (2019) Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience. Therap Adv Gastroenterol. https:\/\/doi.org\/10.1177\/1756284819848631","journal-title":"Therap Adv Gastroenterol"},{"key":"5418_CR13","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1016\/S0140-6736(21)01255-1","volume":"398","author":"N Ruperto","year":"2021","unstructured":"Ruperto N, Brunner HI, Synoverska O et al (2021) Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial. Lancet 398:1984\u20131996. https:\/\/doi.org\/10.1016\/S0140-6736(21)01255-1","journal-title":"Lancet"},{"key":"5418_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/ECI.13959","author":"Z Fu","year":"2023","unstructured":"Fu Z, He Y, Gao L et al (2023) STAT2\/Caspase3 in the diagnosis and treatment of psoriasis. Eur J Clin Invest. https:\/\/doi.org\/10.1111\/ECI.13959","journal-title":"Eur J Clin Invest"},{"key":"5418_CR15","doi-asserted-by":"publisher","DOI":"10.1177\/12034754221141680","author":"WJ Loo","year":"2023","unstructured":"Loo WJ, Turchin I, Prajapati VH et al (2023) Clinical implications of targeting the JAK-STAT pathway in psoriatic disease: emphasis on the TYK2 pathway. J Cutan Med Surg. https:\/\/doi.org\/10.1177\/12034754221141680","journal-title":"J Cutan Med Surg"},{"key":"5418_CR16","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1111\/J.1365-2559.2006.02412.X","volume":"48","author":"T Kirkegaard","year":"2006","unstructured":"Kirkegaard T, Edwards J, Tovey S et al (2006) Observer variation in immunohistochemical analysis of protein expression, time for a change? Histopathology 48:787\u2013794. https:\/\/doi.org\/10.1111\/J.1365-2559.2006.02412.X","journal-title":"Histopathology"},{"key":"5418_CR17","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/J.JAAD.2016.12.005","volume":"76","author":"W Damsky","year":"2017","unstructured":"Damsky W, King BA (2017) JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol 76:736\u2013744. https:\/\/doi.org\/10.1016\/J.JAAD.2016.12.005","journal-title":"J Am Acad Dermatol"},{"key":"5418_CR18","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/J.IMMUNI.2008.03.002","volume":"28","author":"JJ O\u2019Shea","year":"2008","unstructured":"O\u2019Shea JJ, Murray PJ (2008) Cytokine signaling modules in inflammatory responses. Immunity 28:477\u2013487. https:\/\/doi.org\/10.1016\/J.IMMUNI.2008.03.002","journal-title":"Immunity"},{"key":"5418_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0164080","author":"AKA De Medeiros","year":"2016","unstructured":"De Medeiros AKA, Speeckaert R, Desmet E et al (2016) JAK3 as an emerging target for topical treatment of inflammatory skin diseases. PLoS ONE. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0164080","journal-title":"PLoS ONE"},{"key":"5418_CR20","doi-asserted-by":"publisher","DOI":"10.5826\/DPC.1204A178","author":"S Sadeghi","year":"2022","unstructured":"Sadeghi S, Goodarzi A (2022) Various application of Tofacitinib and Ruxolitinib (Janus kinase inhibitors) in dermatology and rheumatology: a review of current evidence and future perspective. Dermatol Pract Concept. https:\/\/doi.org\/10.5826\/DPC.1204A178","journal-title":"Dermatol Pract Concept"},{"key":"5418_CR21","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/J.CGH.2018.10.047","volume":"17","author":"B Kochar","year":"2019","unstructured":"Kochar B, Herfarth N, Mamie C et al (2019) Tofacitinib for the treatment of pyoderma gangrenosum. Clin Gastroenterol Hepatol 17:991\u2013993. https:\/\/doi.org\/10.1016\/J.CGH.2018.10.047","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5418_CR22","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.4049\/JIMMUNOL.0804063","volume":"183","author":"BY Chang","year":"2009","unstructured":"Chang BY, Zhao F, He X et al (2009) JAK3 inhibition significantly attenuates psoriasiform skin inflammation in CD18 mutant PL\/J mice. J Immunol 183:2183\u20132192. https:\/\/doi.org\/10.4049\/JIMMUNOL.0804063","journal-title":"J Immunol"},{"key":"5418_CR23","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/J.INTIMP.2015.12.035","volume":"32","author":"TT Di","year":"2016","unstructured":"Di TT, Ruan ZT, Zhao JX et al (2016) Astilbin inhibits Th17 cell differentiation and ameliorates imiquimod-induced psoriasis-like skin lesions in BALB\/c mice via Jak3\/Stat3 signaling pathway. Int Immunopharmacol 32:32\u201338. https:\/\/doi.org\/10.1016\/J.INTIMP.2015.12.035","journal-title":"Int Immunopharmacol"},{"key":"5418_CR24","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1038\/JID.2011.222","volume":"131","author":"X Shi","year":"2011","unstructured":"Shi X, Jin L, Dang E et al (2011) IL-17A upregulates keratin 17 expression in keratinocytes through STAT1- and STAT3-dependent mechanisms. J Invest Dermatol 131:2401\u20132408. https:\/\/doi.org\/10.1038\/JID.2011.222","journal-title":"J Invest Dermatol"},{"key":"5418_CR25","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/J.JID.2018.11.018","volume":"139","author":"E Witte-H\u00e4ndel","year":"2019","unstructured":"Witte-H\u00e4ndel E, Wolk K, Tsaousi A et al (2019) The IL-1 pathway is hyperactive in hidradenitis suppurativa and contributes to skin infiltration and destruction. J Invest Dermatol 139:1294\u20131305. https:\/\/doi.org\/10.1016\/J.JID.2018.11.018","journal-title":"J Invest Dermatol"},{"key":"5418_CR26","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/J.JAAD.2010.07.010","volume":"65","author":"C Schlapbach","year":"2011","unstructured":"Schlapbach C, H\u00e4nni T, Yawalkar N, Hunger RE (2011) Expression of the IL-23\/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol 65:790\u2013798. https:\/\/doi.org\/10.1016\/J.JAAD.2010.07.010","journal-title":"J Am Acad Dermatol"},{"key":"5418_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2019.02847","author":"F Solimani","year":"2019","unstructured":"Solimani F, Meier K, Ghoreschi K (2019) Emerging topical and systemic JAK inhibitors in dermatology. Front Immunol. https:\/\/doi.org\/10.3389\/FIMMU.2019.02847","journal-title":"Front Immunol"},{"key":"5418_CR28","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1111\/BJD.20969","volume":"186","author":"A Alavi","year":"2022","unstructured":"Alavi A, Hamzavi I, Brown K et al (2022) Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studies. Br J Dermatol 186:803\u2013813. https:\/\/doi.org\/10.1111\/BJD.20969","journal-title":"Br J Dermatol"},{"key":"5418_CR29","doi-asserted-by":"publisher","DOI":"10.1268\/F1000RESEARCH.17267.1","author":"JW Frew","year":"2018","unstructured":"Frew JW, Hawkes JE, Krueger JG (2018) A systematic review and critical evaluation of inflammatory cytokine associations in hidradenitis suppurativa [version 1; referees: 2 approved, 1 approved with reservations]. F1000Research. https:\/\/doi.org\/10.1268\/F1000RESEARCH.17267.1","journal-title":"F1000Research"},{"key":"5418_CR30","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1016\/J.JISP.2020.04.005","volume":"20","author":"CE Hamilton","year":"2020","unstructured":"Hamilton CE, Craiglow BG (2020) JAK inhibitors for the treatment of pediatric alopecia areata. J Investig dermatology Symp Proc 20:S31\u2013S36. https:\/\/doi.org\/10.1016\/J.JISP.2020.04.005","journal-title":"J Investig dermatology Symp Proc"},{"key":"5418_CR31","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/J.JAAD.2022.08.061","volume":"88","author":"B Strober","year":"2023","unstructured":"Strober B, Tha\u00e7i D, Sofen H et al (2023) Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 program for evaluation of TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol 88:40\u201351. https:\/\/doi.org\/10.1016\/J.JAAD.2022.08.061","journal-title":"J Am Acad Dermatol"},{"key":"5418_CR32","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/J.CELS.2016.09.009","volume":"3","author":"SS Shen-Orr","year":"2016","unstructured":"Shen-Orr SS, Furman D, Kidd BA et al (2016) Defective signaling in the JAK-STAT pathway tracks with chronic inflammation and cardiovascular risk in aging humans. Cell Syst 3:374. https:\/\/doi.org\/10.1016\/J.CELS.2016.09.009","journal-title":"Cell Syst"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-023-05418-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-023-05418-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-023-05418-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T11:04:18Z","timestamp":1733310258000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-023-05418-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,10]]},"references-count":32,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5418"],"URL":"https:\/\/doi.org\/10.1007\/s00296-023-05418-y","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,10]]},"assertion":[{"value":"11 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors report no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study was conducted in accordance with the Helsinki Declaration and was approved by the local ethics committee (IRB number: 0166). Written informed consent was obtained from all participants. It was also registered on clinicaltrials.gov with the number NCT04792957.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare that the submitted work is their own and that copyright has not been breached in seeking its publication. This study was presented as an oral presentation during the EULAR 2022 European Congress of Rheumatology, held from June 1\u20134, 2022, in Denmark.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}}]}}